On Nov 05, major Wall Street analysts update their ratings for $Vertex Pharmaceuticals (VRTX.US)$, with price targets ranging from $476 to $600.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $474 to $476.
Barclays analyst Gena Wang maintains with a hold rating, and maintains the target price at $509.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $555.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $525.
Needham analyst Joseph Stringer maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Following Vertex Pharmaceuticals' third-quarter results that surpassed consensus expectations, and the company's updated revenue guidance for 2024 showing a slight increase, the focus for future stock movement is anticipated to be on the upcoming Phase 2 data for suzetrigine in lumbosacral radiculopathy expected by the end of the year.
Here are the latest investment ratings and price targets for $Vertex Pharmaceuticals (VRTX.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
